Agios Pharmaceuticals, Inc. (AGIO) stock
AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)
Close on Nov 17, 2026Market cap $1.78BP/E –Yield –
Agios Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Agios Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $356.75M, up 11.5% year over year. For fiscal 2025 it was $339.54M, up 12.7% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $341.32M in fiscal 2018.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $339.54M | +12.7% |
| FY2024 | Dec 31, 2024 | $301.29M | +1.9% |
| FY2023 | Dec 31, 2023 | $295.53M | +5.6% |
| FY2022 | Dec 31, 2022 | $279.91M | +8.9% |
| FY2021 | Dec 31, 2021 | $256.97M | +16.4% |
| FY2020 | Dec 31, 2020 | $220.81M | +3.1% |
| FY2019 | Dec 31, 2019 | $214.26M | -37.2% |
| FY2018 | Dec 31, 2018 | $341.32M | +16.6% |
| FY2017 | Dec 31, 2017 | $292.68M | +32.9% |
| FY2016 | Dec 31, 2016 | $220.16M | +55.2% |
| FY2015 | Dec 31, 2015 | $141.83M | +41.3% |
| FY2014 | Dec 31, 2014 | $100.37M | +84.2% |
| FY2013 | Dec 31, 2013 | $54.50M | +32.8% |
| FY2012 | Dec 31, 2012 | $41.04M | +31.3% |
| FY2011 | Dec 31, 2011 | $31.25M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $100.75M | +9.6% |
| Q1 FY2026 | Mar 31, 2026 | $81.15M | +11.6% |
| Q4 FY2025 | Dec 31, 2025 | $88.06M | +6.3% |
| Q3 FY2025 | Sep 30, 2025 | $86.80M | +19.8% |
| Q2 FY2025 | Jun 30, 2025 | $91.94M | +18.8% |
| Q1 FY2025 | Mar 31, 2025 | $72.74M | +6.0% |
| Q4 FY2024 | Dec 31, 2024 | $82.81M | +6.9% |
| Q3 FY2024 | Sep 30, 2024 | $72.46M | -11.5% |
| Q2 FY2024 | Jun 30, 2024 | $77.40M | +12.3% |
| Q1 FY2024 | Mar 31, 2024 | $68.62M | +2.0% |
| Q4 FY2023 | Dec 31, 2023 | $77.49M | +10.2% |
| Q3 FY2023 | Sep 30, 2023 | $81.84M | +26.0% |
| Q2 FY2023 | Jun 30, 2023 | $68.90M | -7.6% |
| Q1 FY2023 | Mar 31, 2023 | $67.30M | -4.0% |
| Q4 FY2022 | Dec 31, 2022 | $70.30M | -4.1% |
| Q3 FY2022 | Sep 30, 2022 | $64.97M | +1.5% |
| Q2 FY2022 | Jun 30, 2022 | $74.52M | +20.2% |
| Q1 FY2022 | Mar 31, 2022 | $70.12M | +21.6% |
| Q4 FY2021 | Dec 31, 2021 | $73.30M | +23.4% |
| Q3 FY2021 | Sep 30, 2021 | $64.00M | +23.2% |
| Q2 FY2021 | Jun 30, 2021 | $62.01M | +14.6% |
| Q1 FY2021 | Mar 31, 2021 | $57.67M | +4.2% |
| Q4 FY2020 | Dec 31, 2020 | $59.42M | -44.1% |
| Q3 FY2020 | Sep 30, 2020 | $51.94M | -48.9% |
| Q2 FY2020 | Jun 30, 2020 | $54.09M | -49.6% |
| Q1 FY2020 | Mar 31, 2020 | $55.36M | -42.1% |
| Q4 FY2019 | Dec 31, 2019 | $106.25M | +13.3% |
| Q3 FY2019 | Sep 30, 2019 | $101.67M | +23.1% |
| Q2 FY2019 | Jun 30, 2019 | $107.39M | +23.8% |
| Q1 FY2019 | Mar 31, 2019 | $95.59M | +22.2% |
| Q4 FY2018 | Dec 31, 2018 | $93.81M | +21.5% |
| Q3 FY2018 | Sep 30, 2018 | $82.56M | +13.2% |
| Q2 FY2018 | Jun 30, 2018 | $86.73M | +8.7% |
| Q1 FY2018 | Mar 31, 2018 | $78.22M | +24.7% |
| Q4 FY2017 | Dec 31, 2017 | $77.22M | +19.4% |
| Q3 FY2017 | Sep 30, 2017 | $72.92M | +20.2% |
| Q2 FY2017 | Jun 30, 2017 | $79.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $62.73M | – |
| Q4 FY2016 | Dec 31, 2016 | $64.68M | – |
| Q3 FY2016 | Sep 30, 2016 | $60.64M | – |
See a number that looks wrong?